OncoSeer Diagnostics, Inc. is a biotech startup using novel multiomic biomarkers and AI modeling across our highly annotated cohort to screen, monitor and diagnose immune related adverse events (irAE's) prior to immune checkpoint inhibitor (ICI) treatments. Our aim is to provide oncologists and pharma an informed way to increase access to ICI's in patients having an early-stage cancer, a prior autoimmune disease, or needing combo ICI treatments where access may be resticted.
We are actively seeking technology and industry partnerships with Academic Medical Centers, CRO/Tool/Lab companies, and Pharma.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Dallas, Texas, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.OncoSeer.com
- Keywords
- oncology, diagnostics, biomarkers, cancer, autoimmune toxicity, immune checkpoint inhibitors, Immunology, AI/ML.
- HQ
- Dallas, Texas
Oncoseer Diagnostics, Inc. Questions
Oncoseer Diagnostics, Inc.'s website is http://www.OncoSeer.com
Oncoseer Diagnostics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/oncoseer-diagnostics-inc
Oncoseer Diagnostics, Inc. has
1 employees.
View email and phone details for 1
employees at Oncoseer Diagnostics, Inc..
Oncoseer Diagnostics, Inc.'s industry is
Biotechnology Research
Oncoseer Diagnostics, Inc.'s top competitors are
Twcg,
Campus Innovations Group Llc,
Texas De Peru,
S2 Health Partners Llc,
Rex Instuments™,
Clearsight Therapeutics,
Trugrit Strategies Group,
Helixomer Inc.,
Ishca Health,
Solenic Medical Inc..
Oncoseer Diagnostics, Inc.'s categories are Biotechnology Research
Oncoseer Diagnostics, Inc.'s founding year is 2022
